A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal
The DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.
Abstract
The potential of the benzodiazepine antagonist flumazenil (Ro 15-1788) to lessen persisting benzodiazepine withdrawal symptoms was demonstrated in 11 patients who had been drug free for between 1 month and 5 years. Doses ranging from 0.2 to 2.0 mg divided into three intravenous injections over a few hours relieved long-standing symptoms to varying extents. These included clouded thinking, tiredness, muscular symptoms such as neck tension, cramps and shaking and the characteristic perceptual symptoms of benzodiazepine withdrawal, namely, pins and needles, burning skin, pain and subjective sensations of bodily distortion. Mood disorder, when present, also improved but the reduction in anxiety and depression may have reflected relief of physical symptoms. The onset of maximum response was sometimes delayed by as much as a day but was usually prompt. Side effects were reported to be either absent or typically described as lightheadedness or dizziness, lasted only a few minutes and were usually well tolerated. The benefits last between a few hours and several days despite flumazenil's otherwise short duration of action. However, symptoms did return to varying degrees in most cases, suggesting the need for repeated doses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even nomenclature was confusing, since it was unclear whether these protracted symptoms were a continuation of acute withdrawal, the unmasking of original symptoms, or an entirely new condition [17,52,69].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [69]
In the citing paper
“Acute withdrawal symptoms occurred in up to 100% of participants from studies found in this scoping review [52,61,62], but prolonged symptoms were less frequently reported, occurring in approximately 30% of benzodiazepine patients [17,54,69].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [69]
In the citing paper
“Although not well understood, the rate of this reversal varies between individuals and with exposure duration, perhaps explaining withdrawal durations from weeks to years (Ashton, 1995; Lader & Morton, 1992).”
From Pharmacological principles for safe benzodiazepine and Z-drug dose reduction (2026) · cites this paper as Lader & Morton, 1992
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
A scale to measure locus of control of behaviour
Craig, A. R., Franklin, J. A., & Andrews, G. (1984) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1984.tb01597.x · Cited by 437
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369 · cited 1×
“In most instances the withdrawal is short-lived and mild especially if a longacting benzodiazepine is tapered off after long-term use (Busto et al., 1986; Schweizer et al., 1990).”
BackgroundWithdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367
Self-citationLong-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Benzodiazepine withdrawal symptoms and propranolol
TYRER, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92861-0 · Cited by 297
Benzodiazepine withdrawal: an unfinished story.
Ashton, H. (1984) · BMJ · doi:10.1136/bmj.288.6424.1135 · Cited by 291
Nutt, D. J. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220033004 · Cited by 272
Gradual Withdrawal of Diazepam after Long-Term Therapy
Tyrer, P., Owen, R., & Dawling, S. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92355-3 · Cited by 271
Research works printed but not linked: 8
- 1990, American Psychiatric Association Task Force Report
- Ashton H., 1987, Br Med J, 82, 665
- Ball J.A., 1987, Lancet, 463
- Committee on Safety of Medicines, 1988, Curr Problems, 21, 1
- Dunton A.W., 1988, Eur J Anaesthiol Suppl, 2, 81
- Evans S.M., 1990, The effects of flumazenil (Ro 15-1788) following acute and repeated exposures to lorazepam in healthy volunteers
- Eysenck H.J., 1975, Manual of the Eysenck personality questionnaire
- Rickels K., 1990, Psychopharmacol Bull, 26, 63
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Self-citationWithdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
“[78] Another study Short half-life compounds were associated with focused on precipitating withdrawal by giving rehigher dropout rates, but withdrawal symptoms were no more severe than with longer half-life peated intravenous doses; withdrawal symptoms su-”
BackgroundSelf-citationGumireddy, K., Li, A., Kossenkov, A. V., Sakurai, M., Yan, J., Li, Y., Xu, H., Wang, J., Zhang, P. J., Zhang, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms10715 · Cited by 217
Benzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Metadata
- Authors
- Lader, M. H., & Morton, S. V.
- Affiliations
- Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1992-05
- Volume
- 6
- Issue
- 3
- Pages
- 357-363
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2061430598
- Cited by
- 33
- References
- 37
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2018: 2 · 2016: 3 · 2015: 4 · 2014: 1 · 2012: 2
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- flumazenil, benzodiazepine withdrawal, benzodiazepine antagonists, mood disorders, anxiety, depression, adverse effects, repeated dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. https://app.cochat.ai/papers/10.1177/026988119200600303
- The paper
- Lader, M. H., & Morton, S. V. (1992). A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. Journal of Psychopharmacology. https://doi.org/10.1177/026988119200600303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.